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Conclusions. Patient preparation is crucial for accurate automatic delineation. It’s expected that the bigger the number of library
patients the higher the score of the matching. Careful selection of patients to be added to the atlas and adequate contouring by
the radiation oncologist should be made.
http://dx.doi.org/10.1016/j.rpor.2013.03.475
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Introduction. External beam radiotherapy (EBRT) with coadjuvant hormonal therapy (HT) is a reliable alternative to surgery in
patients with locally advanced prostate cancer.
Purpose. To analyze a case of our service and to review the literature on the efﬁcacy and tolerability of bicalutamide versusmedical
castration, coadjuvant to EBRT.
Methods. Retrospective analysis of a clinical case and review of the literature.
Results. 67 years old patient, diagnosed with high-risk prostate adenocarcinoma: prostate-speciﬁc antigen (PSA) = 25.45ng/ml.
Gleason score: 4 + 5 bilateral. Clinical T3a. Perineural invasion. Negative bone scan. CT: seminal vesicle invasion. Treatment
alternatives: Radical surgery vs EBRT+HT. The patient chooses the RTE because he wants to preserve sexual function. Androgen
deprivation options: central action with RHLH analogues vs peripheric action with bicalutamide. The patient selects the second
for the same reason. After 3 months of HT with bicalutamide 150mgr, PSA nadir is 2.13ng/ml. Then get EBRT on a volume
that covers prostate, seminal vesicles and risk iliac lymph nodes, with good tolerance. Proceed with bicalutamide for three
years. Post-EBRT biochemical control: PSA=1.6ng/ml, without signiﬁcant toxicity. After 24 months of follow up, continuing with
bicalutamide, asymptomatic and sexually active. Mild bilateral gynecomastia and breast pain. Local exploration: ﬁbrotic prostate
nodule in the right lobe. PSA<0.03ng/ml. The HT with EBRT shows a signiﬁcant increase in progression-free survival and overall
survival in patients with locally advanced prostate cancer. Bicalutamide with EBRT reduce the risk of death at similar rates to
medical castration (25–30%). Compared with medical castration, bicalutamide monotherapy provides a higher quality of life and
tolerance, and lower rates of hot ﬂashes, although gynecomastia and breast pain have a higher incidence.
Conclusions. Bicalutamidemonotherapy should be considered as a valid alternative in the hormonal treatment of locally advanced
prostate cancer.
http://dx.doi.org/10.1016/j.rpor.2013.03.476
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Introduction. Brachytherapy for prostate cancer has established itself in recent years as the ﬁrst line treatment in selected patients
with localized prostate cancer.
Objectives. To analyze characteristics and biochemical control of patients treated with 125I brachytherapy since the introduction
of the technique in our department.
Materials and methods. Between July-07 and January-13 a total of 144 implants have been performed. For the study we analyzed
retrospectively 100 patients (minimum follow-up 1 year). We analyzed age, neoadjuvant hormonal therapy, PSA, Gleason score,
T stage, risk group, number and time to nadir and biochemical control (Phoenix criteria). Statistical analysis: We performed a
descriptive study calculating mean and standard deviation for quantitative variables and absolute frequencies and percentages
for qualitative variables. We performed a survival analysis using Kaplan–Meier method to calculate the biochemical control.
Results. Mean age was 64.6±6.6 years (49–75). 17% had started androgen deprivation therapy. Mean PSA was 5.8±1.7ng/ml
(2.4–9.7). Gleason score 6was themost frequent (93%), followed by 5 (4%) and 7 (2%). Distribution by stages: T1c (96%), followed T2a
(4%). Risk group: low (98%), intermediate (2%). Mean nadir was 0.74±0.93ng/ml (0.0–5.8) and median time to reach it 22.2±15.3
months (3.7–57). 6 patients had biochemical recurrence. With a median follow up of 36.4 months (12–64), biochemical control at
2 and 4 years was 97.3% and 86.2% respectively.
Conclusions. 125I brachytherapy as radical treatment in selected patients with localized prostate carcinoma achieves optimal
results in terms of biochemical control. The results obtained in our series are equivalent to those described in the literature.
http://dx.doi.org/10.1016/j.rpor.2013.03.477
